Journal
Frontiers in Immunology
Publication Date
2017
Volume
8
Inclusive Pages
675
Document Type
Open Access Publication
DOI
10.3389/fimmu.2017.00675
Rights and Permissions
Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, London WB, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Miller JS, Gilman AL, Kahl B, Yu AL and Sondel PM (2017) HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy. Front. Immunol. 8:675. doi: 10.3389/fimmu.2017.00675 © 2017 Erbe, Wang, Reville, Carmichael, Kim, Mendonca, Song, Hank, London, Naranjo, Hong, Hogarty, Maris, Park, Ozkaynak, Miller, Gilman, Kahl, Yu and Sondel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Recommended Citation
Kahl, Brad and et al, "HLA-Bw4-I-80 isoform differentially influences clinical outcome as compared to HLA-Bw4-T-80 and HLA-A-Bw4 isoforms in rituximab or dinutuximab-based cancer immunotherapy." Frontiers in Immunology. 8, 675. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/5919
